arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Arcutis Biotherapeutics, Inc.

ARQT
$25.27 ▼ -1.15 (-4.33%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
34
Health
Poor
Bearish
auto_awesome

Analytical Summary

Arcutis Biotherapeutics, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.3M
Dividend Yield
Revenue Growth 60.1%
Op. Margin -8.6%
ROIC -2.4%
FCF / Share $17.31
Trailing P/E
Price / Book 16.7x
FCF Yield 68.5%
Debt / Equity 0.58
info Valuation on last close. End-of-day price, Aug 7, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$105.40M
↑ +60.1%
Net Income Profit after all expenses
$-11.29M
↑ +54.9%
Operating Margin Operating profit as % of sales
-8.6%
↓ -160.7% 22th
FCF / Share Free cash flow per share
$17.31
↑ +126032.0%
Long-Term Debt Long-term obligations
$109.42M
— +0.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
22
Returns
35
Financial Health
45
Cash Quality
35

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters